Phase 4
Completed N=21
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
Source: ClinicalTrials.gov NCT00839540 ↗Enrolled (actual)
21
Serious AEs
9.5%
Results posted
Feb 2012
Primary outcomePrimary: Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 3; 0.5; 0; 3 Log inhibition
Summary
The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is:
To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against Candida glabrata with varying degrees of caspofungin susceptibilities.
This investigation will provide clinicians information supporting the use of caspofungin and micafungin in situations where Candida strains may be a cause of infection.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) |
3; 0.5; 0; 3; 1.5; 0.5 | — |
Eligibility Criteria
Inclusion Criteria
- Adult patients with presumptive candidemia
Exclusion Criteria
- Patients with severe neutropenia ( 20
- Patients with severe liver disease
Data sourced from ClinicalTrials.gov (NCT00839540). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.